ID: h-cb692686e2
Hypothesis

Tau missorting transitions into an autonomous tau-seeding state after transient Aβ exposure

Transient Aβ exposure induces dendritic tau missorting that then converts into a locally self-propagating tau oligomer/seeding program.
🧬 MAPT🩺 neurodegeneration🎯 Composite 74%💱 $0.60▼18.6%proposed
EvidencePending (0%)📖 8 cit🗣 1 debates 8 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.82 (15%) Evidence 0.78 (15%) Novelty 0.72 (12%) Feasibility 0.83 (12%) Impact 0.84 (12%) Druggability 0.80 (10%) Safety 0.62 (8%) Competition 0.58 (6%) Data Avail. 0.74 (5%) Reproducible 0.70 (5%) KG Connect 0.24 (8%) 0.740 composite
🏆 ChallengeResolve: Post-Aβ Clearance Tau Autonomy Determines Efficacy of Anti-Tau Therapy $750K →

🧪 Overview

Transient Aβ exposure induces dendritic tau missorting that then converts into a locally self-propagating tau oligomer/seeding program. After verified Aβ clearance, continued degeneration is driven by tau seed formation, templated misfolding, and trans-synaptic spread rather than by ongoing amyloid signaling.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["MAPT<br/>Primary Target"]
    B["Biological Process 1<br/>Mechanistic Step A"]
    C["Biological Process 2<br/>Mechanistic Step B"]
    D["Output Phenotype<br/>Disease Effect"]
    A --> B
    B --> C
    C --> D
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix8 supports2 contradicts
Supports
Tau oligomer formation and propagation are well supported, making an autonomous post-trigger seeded state biologically plausible.
Supports
Aβ can heterotypically seed or accelerate tau propagation, supporting an initiator-to-seeding transition model.
Supports
Aβ oligomers induce tau missorting and spine pathology, providing the upstream state from which autonomous seeding could emerge.
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Lab Invest2019PMID:30742061medium
Supports
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy2023PMID:36843263medium
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med2023PMID:37095250medium
Supports
ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.
Cell2021PMID:34314701medium
Supports
The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
Alzheimers Dement2024PMID:38556838medium
Contradicts
Direct proof that transient Aβ exposure alone creates a self-sustaining tau-seeding state after complete Aβ removal remains limited.
Contradicts
Many tau-seeding systems rely on overexpression or persistent pathology, leaving Aβ-independent persistence unresolved.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MAPT

🧬 PDB 5O3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Cerebellum209 Cerebellar Hemisphere199 Cortex152 Frontal Cortex BA9146 Anterior cingulate cortex BA24101 Hypothalamus86.4 Amygdala73.5 Nucleus accumbens basal ganglia72.2 Hippocampus72.1 Caudate basal ganglia64.7 Putamen basal ganglia58.1 Substantia nigra56.8 Spinal cord cervical c-149.2median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.3%
Volatility
Low
0.0075
Events (7d)
3
Price History
▼18.6%

💾 Resource Usage

LLM Tokens
17,362
$0.0521
Total Cost
$0.0521

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF APP/PS1dE9 mice receive anti-tau antibody (HJ8.5, 10mg/kg, i.p.) or tau siRNA delivered via AAV9-CamKIIa-eGFP throughout the 30-day period following transient intracerebroventricular Aβ infusion (cEquivalent neurodegeneration (CA1 neuronal density ≤60% of baseline) and equivalent spatial memory deficits (Barnes maze latency ≥45 sec) in anti-tau/knockdown — no observation —pending0.58
IF primary cortical neurons are exposed to 1 μM Aβ42 oligomers for 48 hours followed by complete washout and verified Aβ clearance (by ELISA), THEN neuronal lysates collected 14 days post-clearance wiIncreased tau seeding activity (≥2-fold FRET signal) in neuronal lysates at day 14 post-Aβ washout— no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF primary cortical neurons are exposed to 1 μM Aβ42 oligomers for 48 hours followed by complete washout and verified Aβ clearance (by ELISA), THEN neuronal lysates collected 14 days post-clearance will show significant tau seeding activity in a FRET-based biosensor assay compared to vehicle-exposed
Predicted outcome: Increased tau seeding activity (≥2-fold FRET signal) in neuronal lysates at day 14 post-Aβ washout
Falsification: No detectable tau seeding activity in neuronal lysates 14 days after Aβ clearance, or seeding activity equivalent to baseline levels in vehicle controls
pendingconf 58%
IF APP/PS1dE9 mice receive anti-tau antibody (HJ8.5, 10mg/kg, i.p.) or tau siRNA delivered via AAV9-CamKIIa-eGFP throughout the 30-day period following transient intracerebroventricular Aβ infusion (cleared by day 3), THEN hippocampal CA1 neuronal counts and behavioral deficits will not differ from
Predicted outcome: Equivalent neurodegeneration (CA1 neuronal density ≤60% of baseline) and equivalent spatial memory deficits (Barnes maze latency ≥45 sec) in anti-tau/
Falsification: Significant reduction in neurodegeneration (CA1 density >75% of baseline) and/or normalization of behavioral performance (Barnes maze latency <30 sec) in tau-blocking groups compared to Aβ-only mice,
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.